Intervenciones para el tratamiento de la colestasis intrahepática en pacientes con anemia de células falciformes
Referencias
Additional references
Akinsheye I, Klings ES. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. Journal of Cellular Physiology 2010;224(3):620‐5. [PUBMED: 20578237]
Alderson P, Roberts I. Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury research. British Medical Journal 2000;320:376‐7. [PUBMED: 10657341]
Alderson P. Absence of evidence is not evidence of absence. British Medical Journal 2004;328:476‐7. [PUBMED: 14988165]
Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;32(5):897‐900. [PUBMED: 11050036]
Azar S, Wong TE. Sickle cell disease: a brief update. The Medical Clinics of North America 2017;101(2):375‐93. [PUBMED: 28189177]
Azzaroli F, Turco L, Lisotti A, Calvanese C, Mazzella G. The pharmacological management of intrahepatic cholestasis of pregnancy. Current Clinical Pharmacology 2011;6(1):12‐7. [PUBMED: 21352094]
Baichi MM, Arifuddin RM, Mantry PS, Bozorgzadeh A, Ryan C. Liver transplantation in sickle cell anemia: a case of acute sickle cell intrahepatic cholestasis and a case of sclerosing cholangitis. Transplantation 2005;80(11):1630‐2. [PUBMED: 16371935]
Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World Journal 2012;2012:949535. [PUBMED: 22924029]
Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401‐6. [PUBMED: 21208779]
Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636‐40. [PUBMED: 22511692]
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9. [PUBMED: 18411040]
Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98. [PUBMED: 18824466]
Brunetta DM, Silva‐Pinto AC, do Carmo Favarin de Macedo M, Bassi SC, Piccolo Feliciano JV, Ribeiro FB, et al. Intrahepatic cholestasis in sickle cell disease: a case report. Anemia 2011;2011:975731. [PUBMED: 21490769]
Caboot JB, Allen JL. Hypoxemia in sickle cell disease: significance and management. Paediatric Respiratory Reviews 2014;15(1):17‐23. [PUBMED: 24461342]
Carey EJ, Lindor KD. Current pharmacotherapy for cholestatic liver disease. Expert Opinion on Pharmacotherapy 2012;13(17):2473‐84. [PUBMED: 23094715]
Chalmers I. Well informed uncertainties about the effects of treatments. How clinicians and patients respond?. BMJ 2004;328:475‐6. [PUBMED: 14988164]
Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet 2014;383(9912):156‐65. [PUBMED: 24411644]
Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. British Medical Journal 2013;346:e7586. [PUBMED: 23303884]
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza‐Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200‐7. [PUBMED: 23295957]
Chitturi S, George J, Ranjitkumar S, Kench J, Benson W. Exchange transfusion for severe intrahepatic cholestasis associated with sickle cell disease?. Journal of Clinical Gastroenterology2002; Vol. 35, issue 4:362‐3. [PUBMED: 12352306]
Costa DB, Miksad RA, Buff MS, Wang Y, Dezube BJ. Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African‐American patient. Journal of the National Medical Association 2006;98(7):1183‐7. [PUBMED: 16895293]
Creary M, Williamson D, Kulkarni R. Sickle cell disease: current activities, public health implications, and future directions. Journal of Women's Health 2007;16:575‐82. [PUBMED: 17627395]
TSA ‐ Trial Sequential Analysis. Copenhagen Trial Unit, Center for Clinical Intervention Research. http://ctu.dk/tsa/ (accessed 29 September 2011).
Danielson CF. The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. Therapeutic Apheresis 2002;6(1):24‐31. [PUBMED: 11886573]
Delis SG, Touloumis Z, Bourli A, Madariaga J, Dervenis C. Can exchange transfusions treat postoperative intrahepatic colestasis in patients with sickle cell anemia?. Transplantation Proceedings 2006;38(5):1385‐6. [PUBMED: 16797311]
Diringer MN. Evidence‐based medicine: what do you do when there's no evidence?. Critical Care Medicine 2003;31(2):659‐60. [PUBMED: 12576991]
Donghaile DO, Klein HG. Hemapheresis. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J editor(s). Hematology: Basic Principles and Practice. 6th Edition. Philadelphia: Saunders, 2013:1716‐26. [ISBN: 978‐1‐4377‐2928‐3]
Easterbrook PJ, Berlin J, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867‐72. [PUBMED: 1672966]
Ebert EC, Nagar M, Hagspiel KD. Gastrointestinal and hepatic complications of sickle cell disease. Clinical Gastroenterology and Hepatology 2010;8(6):483‐9; quiz e70. [PUBMED: 20215064]
Emre S, Kitibayashi K, Schwartz ME, Ahn J, Birnbaum A, Thung SN, et al. Liver transplantation in a patient with acute liver failure due to sickle cell intrahepatic cholestasis. Transplantation 2000;69(4):675‐6. [PUBMED: 10708131]
Gabriel SE, Normand SL. Getting the Methods Right ‐ The Foundation of Patient‐Centered Outcomes Research. New England Journal of Medicine 2012;367(9):787‐90. [PUBMED: 22830434]
Gardner K, Suddle A, Kane P, O'Grady J, Heaton N, Bomford A, et al. How we treat sickle hepatopathy and liver transplantation in adults. Blood 2014;123(15):2302‐7. [PUBMED: 24565828]
Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World Journal of Gastroenterology2009; Vol. 15, issue 17:2049‐66. [PUBMED: 19418576]
Glasziou P, Chalmers I. Can it really be true that 50% of research is unpublished?. http://blogs.bmj.com/bmj/2017/06/05/paul‐glasziou‐and‐iain‐chalmers‐can‐it‐really‐be‐true‐that‐50‐of‐research‐is‐unpublished/?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork (accessed 12 June 2017).
Gluud C. "Negative trials" are positive!. Journal of Hepatology 1998;28(4):731‐3. [PUBMED: 9566846]
Goodman SR, Daescu O, Kakhniashvili DG, Zivanic M. The proteomics and interactomics of human erythrocytes. Experimental Biology and Medicine 2013;238(5):509‐18. [PUBMED: 23856902]
GRADE [Computer program]. Brozek J, Oxman A, Schünemann H. Version 3.6 for Windows2008.
Gutsaeva DR, Montero‐Huerta P, Parkerson JB, Yerigenahally SD, Ikuta T, Head CA. Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability. Blood 2014;123(12):1917‐26. [PUBMED: 24429338]
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology 2011;64(12):1283‐93. [PUBMED: 21839614]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302. [PUBMED: 21803546]
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence‐‐publication bias. Journal of Clinical Epidemiology 2011;64(12):1277‐82. [PUBMED: 21802904]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence‐‐indirectness. Journal of Clinical Epidemiology 2011;64(12):1303‐10. [PUBMED: 21802903]
Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso‐Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311‐6. [PUBMED: 21802902]
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso‐Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence‐‐study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407‐15. [PUBMED: 21247734]
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [PUBMED: 21195583]
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395‐400. [PUBMED: 21194891]
Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380‐2. [PUBMED: 21185693]
Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines 11‐making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2012;66(2):151‐157. [PUBMED: 22542023]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. British Medical Journal 2003;327(7414):557‐60. [PUBMED: 12958120]
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane‐handbook.org.
Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. British Medical Journal 1999;319(7211):670‐4. [PUBMED: 10480822]
Horn A, Freed N, Pecora AA. Sickle cell hepatopathy: diagnosis and treatment with exchange transfusion. Journal of the American Osteopathic Association 1987;87(2):130‐3. [PUBMED: 3558021]
International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997.
Im DD, Essien U, DePasse JW, Chiappa V. Acute on chronic liver failure in a patient with sickle cell anaemia (HbSS). BMJ Case Reports2015; Vol. 2015:Jul 1. [PUBMED: 26135492]
Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. [PUBMED: 15545678]
Ioannidis JP. The art of getting it wrong. Research Synthesis Methods 2010;1(3‐4):169‐84.
Johnson CS, Omata M, Tong MJ, Simmons JF, Weiner J, Tatter D. Liver involvement in sickle cell disease. Medicine 1985;64(5):349‐56. [PUBMED: 4033412]
Kaplan A. Complications of apheresis. Seminars in Dialysis 2012;25(2):152‐8. [PUBMED: 22321209]
Karunatilake H, Vithiya K, Malavan R, Natalia H, Ratnayake H. Exchange transfusion for intrahepatic cholestasis due to sickle beta thalassaemia. Ceylon Medical Journal 2009;54(3):95‐6. [PUBMED: 19999791]
Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annual Review of Medicine 2013;64:451‐66. [PUBMED: 23190149]
Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis‐associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107(6):2279‐85. [PUBMED: 16291595]
Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews 2007;21:37‐47. [PUBMED: 17084951]
Kato GJ, Gladwin MT. Evolution of novel small‐molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008;300(22):2638‐46. [PUBMED: 19066384]
Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology2009; Vol. 84, issue 9:618‐25. [PUBMED: 19610078]
Kato GJ. No NO means yes to sickle red cell adhesion. Blood 2014;123(12):1780‐2. [PUBMED: 24652963]
Khan MA, Kerner JA. Reversal of hepatic and renal failure from sickle cell intrahepatic cholestasis. Digestive Diseases and Sciences 2011;56(6):1634‐6. [PUBMED: 21267779]
Khurshid I, Anderson L, Downie GH, Pape GS. Sickle cell disease, extreme hyperbilirubinemia, and pericardial tamponade: case report and review of the literature. Critical Care Medicine 2002;30(10):2363‐7. [PUBMED: 12394969]
Kleinman SH, Hurvitz CG, Goldfinger D. Use of erythrocytapheresis in the treatment of patients with sickle cell anemia. Journal of Clinical Apheresis 1984;2(2):170‐6. [PUBMED: 6543585]
Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. Journal of Clinical Apheresis 2012;27(3):117‐25. [PUBMED: 22532037]
Lockwood SY, Erkal JL, Spence DM. Endothelium‐derived nitric oxide production is increased by ATP released from red blood cells incubated with hydroxyurea. Nitric Oxide 2014;38:1‐7. [PUBMED: 24530476]
Lottenberg R, Hassell KL. An evidence‐based approach to the treatment of adults with sickle cell disease. Hematology / The Education Program of the American Society of Hematology. American Society of Hematology. Education Program2005:58‐65. [PUBMED: 16304360]
Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, et al. Biomedical research: increasing value, reducing waste. Lancet 2014;383(9912):101‐4. [PUBMED: 24411643]
Malik A, Merchant C, Rao M, Fiore RP. Rare but lethal hepatopathy‐sickle cell intrahepatic cholestasis and management strategies. The American Journal of Case Reports 2015;16:840‐3. [PUBMED: 26613743]
Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008;86:480‐7. [PUBMED: 18568278]
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 2010;63(8):e1‐37. [PUBMED: 20346624]
Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2008, issue 1:177‐85. [PUBMED: 19074078]
Morris CR. Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. Hematology/Oncology Clinics of North America 2014;28(2):301‐21. [PUBMED: 24589268]
Muriel P, Rivera‐Espinoza Y. Beneficial drugs for liver diseases. Journal of Applied Toxicology 2008;28(2):93‐103. [PUBMED: 17966118]
Dufour DR (editor). The National Academy of Clinical Biochemistry. Laboratory guidelines for screening, diagnosing and monitoring for hepatic injury. Laboratory Medicine Practice Guidelines2000; Vol. 12:1‐61.
Expert panel report. Evidence‐based management of sickle cell disease. www.nhlbi.nih.gov/health‐pro/guidelines/sickle‐cell‐disease‐guidelines/ (Access: 20 November 2014)2014.
Nishank SS, Singh MP, Yadav R, Gupta RB, Gadge VS, Gwal A. Endothelial nitric oxide synthase gene polymorphism is associated with sickle cell disease patients in India. Journal of Human Genetics 2013;58(12):775‐9. [PUBMED: 24088668]
O'Callaghan A, O'Brien SG, Ninkovic M, Butcher GP, Foster CS, Walters JR, et al. Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. Gut 1995;37(1):144‐7. [PUBMED: 7672666]
Omata M, Johnson CS, Tong M, Tatter D. Pathological spectrum of liver diseases in sickle cell disease. Digestive Diseases and Sciences 1986;31(3):247‐56. [PUBMED: 3948629]
Patel DK, Mohapatra MK, Thomas AG, Patel S, Purohit P. Procalcitonin as a biomarker of bacterial infection in sickle cell vaso‐occlusive crisis. Mediterranean Journal of Hematology and Infectious Diseases 2014;6(1):e2014018. [PUBMED: 24678395]
Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: “Our questions, our decisions: Standards for patient‐centered outcomes research”. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 07 July 2014):1‐61.
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. The New England Journal of Medicine 2017;376(16):1561‐73. [PUBMED: 28423290]
Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.
Sarode R, Altuntas F. Blood bank issues associated with red cell exchanges in sickle cell disease. Journal of Clinical Apheresis 2006;21(4):271‐3. [PUBMED: 17177280]
Savafi NA, Akbulut S, Koseoglu T, Albayrak L. Chronic liver disease in a patient with sickle cell anemia. Turkish Journal of Gastroenterology 2006;17(2):123‐5. [PUBMED: 16830296]
Sheehy TW, Law DE, Wade BH. Exchange transfusion for sickle cell intrahepatic cholestasis. Archives of Internal Medicine 1980;140(10):1364‐6. [PUBMED: 7425771]
Simon E, Long B, Koyfman A. Emergency medicine management of sickle cell disease complications: an evidence‐based update. The Journal of Emergency Medicine 2016;51(4):370‐81. [PUBMED: 27553919]
Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. Scientific World Journal 2009;9:46‐67. [PUBMED: 19151898]
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. British Medical Journal 2011;343:d4002. [PUBMED: 21784880]
Sun K, Xia Y. New insights into sickle cell disease: a disease of hypoxia. Current Opinion in Hematology 2013;20(3):215‐21. [PUBMED: 23549375]
Swerdlow PS. Red cell exchange in sickle cell disease. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2006:48‐53. [PUBMED: 17124039]
Thakur TJ, Guindo A, Cullifer LR, Li Y, Imumorin IG, Diallo DA, et al. Endothelin‐1 but not endothelial nitric oxide synthase gene polymorphism is associated with sickle cell disease in Africa. Gene Regulation and Systems Biology 2014;8:119‐26. [PUBMED: 24932102]
Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38(1):276‐86. [PUBMED: 18824467]
Thorlund K, Anema A, Mills E. Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology 2010;2:57‐66. [PUBMED: 20865104]
Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User Manual for Trial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf (accessed 30 April 2012).
Tiftik N, Altintas E, Kiykim A, Ucbilek E, Sezgin O. Long‐term red blood cell exchange can be used to successfully treat sickle cell intrahepatic cholestasis: a case report. Journal of Clinical Apheresis 2004;19(1):17‐9. [PUBMED: 15095397]
Tluway F, Makani J. Sickle cell disease in Africa: an overview of the integrated approach to health, research, education and advocacy in Tanzania, 2004‐2016. British Journal of Haematology 2017;177(6):919‐29. [PUBMED: 28295224]
Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.MR000030.pub2]
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet2017; Vol. Epub ahead of print. [PUBMED: 28159390]
Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited Disorders of Hemoglobin. Disease Control Priorities in Developing Countries. 2nd Edition. Washington DC: The World Bank and Oxford University Press, 2006.
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. [PUBMED: 18083463]
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080]
Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology 2017;17(1):39. [PUBMED: 28264661]
World Health Organization. 59th World Health Assembly resolution WHA59.20 on sickle cell anaemia. http://apps.who.int/gb/ebwha/pdf_files/WHA59‐REC1/e/Resolutions‐en.pdf (accessed December 14, 2012):1‐40.
Yawn BP, Buchanan GR, Afenyi‐Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members.. JAMA 2014;312(10):1033‐48. [PUBMED: 25203083]
Zhang Y, Xia Y. Adenosine signaling in normal and sickle erythrocytes and beyond. Microbes and Infection 2012;14(10):863‐73. [PUBMED: 22634345]
References to other published versions of this review
Ir a:
Martí‐Carvajal AJ, Simancas‐Racines D. Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2]
